Duplication cited in generic field

Problems like duplicate R&D and applications abound in the generic-drug field, according to a report issued by the country's drug evaluation center.

The center, under the China Food and Drug Administration, issued a report that noted a 30 percent rejection rate of all drug applications in 2012.

The center's major tasks include evaluation and supervision of human clinical trials of drugs for which government approval is sought.